Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. - Hong SD; Wang YS; Zhao HY; Zhao YY; Wang QM; Ma YX; Li YS; Huang Y; Yang YP; Fu ZM; Chen LK; Zhou F; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2026)